Median survival time of patients after transcatheter chemo-embolization for hepatocellular carcinoma

Journal of the College of Physicians and Surgeons Pakistan

Volumn 16, Issue 4, 2006, Pages 265-269

  Haider, Zishan ^a   ul Haq, Tanveer ^a   Munir, Khalid ^a   Usman, M Uzair ^a   Azeemuddin, Muhammad ^a  

^a AGA KHAN UNIVERSITY HOSPITAL   (Pakistan)

Author keywords

Hepatocellular carcinoma (HCC); Hepatoma median survival time; Transarterial chemoembolization (TACE)

Indexed keywords

ALPHA FETOPROTEIN; EPIRUBICIN; MITOMYCIN C; POLYVINYL ALCOHOL;

ADULT; AGED; ALOPECIA; ARTICLE; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CHEMOEMBOLIZATION; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; CONFIDENCE INTERVAL; DRUG FEVER; FEMALE; FOLLOW UP; HUMAN; LIVER BIOPSY; LIVER CELL CARCINOMA; LONGITUDINAL STUDY; MALE; NAUSEA; PAKISTAN; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; COHORT STUDIES; DEVELOPING COUNTRIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER NEOPLASMS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PAKISTAN; PALLIATIVE CARE; PROBABILITY; RISK ASSESSMENT; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 33745296670     PISSN: 1022386X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. I. D'Agostino HB, Solinas A. Percutaneous ablation therapy for hepatocellular carcinomas. AJR Am J Roentgenol 1995; 164: 1165-7.
2. Khokhar N, Aijazi I, Gill ML. Spectrum of hepatocellular carcinoma at Shifa International Hospital, Islamabad. J Ayub Med Coll (Abbottabad). 2003; 15(4): 1-4.
3. Xavier Bosch F. Global epidemiology of hepatocellular carcinoma. In: Okuda K, Tabor E, (edi). Liver cancer. New York: Churchill Livingstone, 1997; 13-28.
4. The liver cancer study group of Japan. Survey and follow up study of primary liver cancer in Japan: report 14. Acta Hepatol Jpn 2000; 41:799-811.
5. Lo CM, Ngan H, Tso WK, LiuCL, Lam CM, Poon RT, et al. Randomized controlled trial of transarterial lipoidal chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35: 1164-70.
6. Takayasu K, Muramatsu Y, Maeda T, Iwata R, Furukawa H, Muramatus Y, et al. Target transarterial oily chemoembolization for small foci of hepatacellular carcinoma using a unified helical CT and angiography system: analysis of factors effecting local recurrence and survival rates. AJR Am J Roentgenol 2001; 176: 681-8.
7. Levy I, Greig PD, Gallinger S, Langer B, Sherman M. Resection of hepatocellular carcinoma without pre-operative tumor biopsy. Ann Surg 2001; 234: 206-9.
8. Okuda S. Transcatheter arterial embolization for advanced hepatocellular carcinoma: the controversy continues (editorial). Hepatolgy 1998; 27: 1743-4.
9. Matsui O, Kadoya M. Kameyama T, Yoshikawa J, Takashima T, Nakanuma Y, et al. Benign and malignant nodules in cirrhotic livers: distinction based on blood supply. Radiology 1991; 178: 493-7.
10. Kan Z, Sato M, Ivancev K. Distribution and effect of iodized poppy seed oil in the liver after hepatic artery embolization: experimental study in several animal species. Radiology 1993; 186: 861-6.
11. Roul JL, Bourguet P, Bretagne JF. Hepatic artery injection of 1-131-labeled lipiodol. I. Bio-distribution study results in patents with hepatocellular carcinoma and liver metastases. Radiology 1988; 168: 541-5.
12. Bruix J, Castells A, Montanya X. Phase II study of transarterial embolization in European patients with hepatocellular carcinoma: need for controlled trials. Hepatology 1994; 20: 643-50.
13. Vetter D, Wenger JJ, Bergier JM, Doffoel M, Bockel R. Transcatheter oily chemoembolization in the management of advanced hepatocellular carcinoma in cirrhosis: results of a western comparative study in 60 patents. Hepatology 1991; 13: 427-33.
14. Bruneton A Berboul P, Grimaldi C, Butori B, Rampal P, Delmont J, et al. Hepatic intra-arterial lipiodol and CT of hepatic tumors: diagnostic and therapeutic value. Radiology 1985; 157: 313-6.
15. Nakamura H, Hashimoto T, Oi H, Sawada S. Transcatheter oily chemoembolization of hepatocellular carcinoma. Radiology 1989; 170: 783-6.
16. Figueras J, Vallas C, Pamies JJ, Benasco C, Sancho C, Rafecas A, et al. Transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma. Rev Esp Eufarm Dig 1993; 83: 215-9.
17. Amorati P. Gross pathologic types of hepatocellular carcinoma in Italian patients: relationship with demographic environmental and clinical factors. Cancer 1993; 72: 1557-63.
18. Okuda K. Primary liver cancer. Ouadrennial review lecture. Dig Dis Sci 1986; 31(9 suppl): 133S-46S.
19. Rose DM, Chapman WC, Brockenbrough AT, Wright JK, Rose AT, Meranze S, et al. Transcatheter arterial chernoembolization as primary treatment for hepatocellular carcinoma. Am J Surg 1999; 177: 405-10.
20. Marcos-Alvarez A, Jenkins RL, Washburn WK. Multimodality treatment of hepatocellular carcinoma in a hepatobillary speciality center. Arch Sug 1996; 131: 292-8.
21. Ryder SD, Rizzi PM, Metivier E. Chemoembolization with lipoidol and doxorubicin: applicability in British patients with hepatocellular carcinoma. Gut 1996; 38: 125-8.
22. Stefanini GF, Amorati P, Biselli Mm Mucci F, Cell A, Arienti V, et al. Efficacy of transarterial targeted treatments on survival of patients with hepatocellular carcinoma: an Italian experience. Cancer 1995; 75: 2427-34.
23. A comparison of lipoidol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. Group d'Etude et do Traitement du Carcinome Hepatocellulaire. New Eng J Med 1995; 332: 1256-61.
24. Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment: study of 850 patients. Cancer 1985; 56: 819-28.
25. Pelletier G, Roche A, Ink O, Anciaux ML, Derhy S, Rougier P, et al. A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Hepatol 1990; 11: 181-4.
26. Ikeda K, Inoue H, Yano T, Kobayashi H, Nakajo M, et al. Comparison of the anticancer effect of ADMOS alone and ADMOS with CDPP in the treatment of hepatocellular carcinoma by intra-arterial injection. Cancer Chemother Pharmacol 1992; 31 (suppl): S65-S8.
27. Simonetti RG, Liberati A, Angiolini C, Pagliaro L. Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials. Ann Oncol 1997; 8: 117-36.
28. Trinchet JC, Ganne-Carrie N, Beaugrand M. Intra-arterial chemoembolization in patients with hepatocellular carcinoma. Hepatogastroenterology 1998; 45: 1242-7.
29. Trevisani F, De Notariis S, Rossi C, Bernardi M. Randomized control trials on chemoembolization for hepatocellular carcinoma: is there room for new studies? J Clin Gastroenterol 2001; 32: 383-9.
30. Bruix J, Liovet J, Castells A, Montana X, Bru C, Ayuso MC, et al. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology 1998; 27: 1578-83.
31. Bronowicki JP, Vetter D, Dumas F, Boudjema K, Bader R, Weiss AM, et al. Transcatheter oily chemoembolizaton for hepatocellular carcinoma: a 4 years study of 127 patents. Cancer 1994; 74:16-24
32. Bronowichi JP, Boudjema K, Chone L, Nisand G, Bazin C, Pflumio F, et al. Comparison of resection, liver transplantation and transcatheter oily chemoembolization in the treatment of helpatocellular carcinoma. J Hepatol 1996; 24: 293-300.
33. Stuart KE, Anand AJ, Jenkins RL. Hepatocellular carcinoma in the United States: prognostic features, treatment outcome, and survival. Cancer 1996; 77: 2217-22.